Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.9% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
8
users have liked this narrative
0
users have commented on this narrative
36
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.0% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Fluor
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Urban Solutions And LNG Canada Will Shape Outlook Amid Risks
Key Takeaways The company's new strategy focusing on cash generation and earnings growth is likely to improve net margins and enhance earnings. Expansion into strategic markets, coupled with project completions and acquisitions, is expected to increase revenue and enhance shareholder value.
View narrative
US$49.89
FV
16.7% undervalued
intrinsic discount
6.22%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
15
users have followed this narrative
about 20 hours ago
author updated this narrative
Organon
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Rising Women's Health Demand And Telemedicine Will Fuel Global Access
Key Takeaways Rapid scaling of women's health products and digital health investments positions Organon for global leadership and sustainable high-margin growth beyond current expectations. Outperformance in biosimilars and manufacturing transformation is set to drive margin expansion, recurring cash flows, and greater market share through aggressive growth strategies.
View narrative
US$18.00
FV
47.8% undervalued
intrinsic discount
1.79%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
6 days ago
author updated this narrative
Exponent
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Technological Complexity And Regulatory Demand Will Expand Consulting Markets
Key Takeaways Accelerating innovation cycles and technical complexity position Exponent for premium growth, as rising demand for its expertise drives stronger pricing power and high-margin, recurring contracts. Expansion into emerging technology verticals and investments in talent enable scalable growth, improved utilization, and structural gains in revenue predictability and sustainable earnings.
View narrative
US$100.00
FV
29.3% undervalued
intrinsic discount
6.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Badger Meter
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Urbanization And Water Scarcity Will Fuel Digital Metering
Key Takeaways Accelerating digital adoption, regulatory demand, and water scarcity are expanding Badger Meter's market and enabling premium pricing, driving sustained margin and recurring revenue growth. Strategic investments in AI, software, and lifecycle platforms position Badger Meter for long-term market leadership and earnings resilience through differentiated, higher-margin offerings.
View narrative
US$265.00
FV
27.9% undervalued
intrinsic discount
9.22%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Lantheus Holdings
AN
AnalystHighTarget
Consensus Narrative from 13 Analysts
Pylarify And Theranostics Expansion Will Capture Global Aging Demand
Key Takeaways Product innovation and expanded diagnostics are set to drive outsized growth, with new formulations and disease area leadership deepening market penetration and competitive positioning. Strategic acquisitions, global expansion, and advanced technology integration position Lantheus to deliver durable, above-market earnings with resilient competitive advantages.
View narrative
US$159.00
FV
66.2% undervalued
intrinsic discount
10.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Vail Resorts
AN
AnalystHighTarget
Consensus Narrative from 11 Analysts
Digital And Experiential Trends Will Shape Four-Season Resorts
Key Takeaways Accelerated cost efficiencies and superior execution are set to raise profit margins beyond current forecasts, driven by strong leadership and operational focus. Investments in guest experience, technology, and four-season offerings will fuel sustained revenue growth, elevate brand loyalty, and boost both asset utilization and profitability.
View narrative
US$235.31
FV
35.2% undervalued
intrinsic discount
5.96%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Exelixis
AN
AnalystHighTarget
Consensus Narrative from 19 Analysts
Aging Demographics And Precision Medicine Will Transform Global Oncology
Key Takeaways Strong market position and pipeline prioritization set the stage for substantial growth in oncology, with new therapies expected to surpass current flagship products. Solid financial health and strategic flexibility enable both opportunistic expansion and shareholder returns, reinforcing long-term earning potential.
View narrative
US$58.68
FV
34.4% undervalued
intrinsic discount
19.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
6 days ago
author updated this narrative
Halozyme Therapeutics
AN
AnalystHighTarget
Consensus Narrative from 9 Analysts
Chronic Disease Trends Will Ignite Subcutaneous Drug Delivery
Key Takeaways Surging partner launches and healthcare trends drive faster-than-expected royalty and product growth, with consensus underestimating Halozyme's market penetration and recurring revenues. Strategic pipeline shifts and expanding eligibility for biologic transformations position Halozyme to dominate drug delivery standards and extend high-margin revenue streams into future decades.
View narrative
US$91.00
FV
28.0% undervalued
intrinsic discount
21.95%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Cirrus Logic
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
IoT And AR/VR Expansion Will Fuel Premium Audio Despite Risks
Key Takeaways Sustained leadership in smartphone audio and expanding high-value content across devices position Cirrus Logic for outperformance in revenue and margin growth. Broadening into mixed-signal, emerging endpoints, and AI-driven user experiences offers diversification, enhances customer mix, and opens new high-margin market opportunities.
View narrative
US$140.00
FV
19.9% undervalued
intrinsic discount
-0.56%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Value any company in seconds
Popular companies